Immuron (IMRNW)

[hondaboost]

IMRNW expires on June 8. Then, cancelled. The buyers are fools.

[hondaboost]

Those buyers are either no-brain or stupid, as IMRNW is worth minus -$8. They're buying it as toilet paper? LOL!

[hondaboost]

Yep, they’re fooling some idiots or naives to buy their shhhitts. Lol!

[Pisd]

Some whale manipulating low volume to entice others imo...

[hondaboost]

Exactly! Immu-Moron May be closed. IMRNW strike prices are $10.8 while IMRN is only $2,8 currently, so, IMRNW is worth of -$8 (minus $8)!
Can’t believe that Some idiots are buying this shhhittt which is not even worth of toilet paper. Lol!

[Pisd]

Too bad huge disappointment the covid pill...

[Pisd]

Little "fat finger" yesterday?, agree stay away here, gl...

[hondaboost]

IMRNW(warrant) expires on Aug 6, then going to Zero. Actually, it’s worth of Zero currently.

[Pisd]

My feeling exactly.. bullish the warrants imo.. IMRNW$ ...

[retireat40]

Could be ugly today. IMRN got crushed after hours and pre-market.

[Kauri]

$IMRN Trading $16-$20 & $IMRNW warrants trade at $2.50 ?? with a $10 exercise price for 2 more years?? $IMRNW should be $7+ARBITRAGE?? Bullish

[Kauri]

$IMRNW $2+ time value

[Kauri]

🇺🇸 The US Department of Defense has reported that @ImmuronLtd's $IMC Travelan® product demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia, indicating broad potential for prevention of travellers' diarrhea: https://t.co/gYsp3WYl4K pic.twitter.com/x7uYaIjYs0

— NWR Communications (@NWRcomms) September 4, 2019

Very bullish

[agru]

Today Immuron obtained issued U.S. Patent No. 9,943,597 related to treatment of NASH.

[Kauri]

Immuron has 4 ongoing Phase 2 trials. 3 Phase trials in NASH in progress, and another blockbuster indication Cdiff (Better product than $MCRB imo)
Of the NASH trials, two of which were selected to be fully funded by the National Institute of Health. Alcoholic fatty liver disease, Non alcoholic fatty liver disease, Pedriatric fatty liver disease.
Dr Arun Sanyal is Chair of NIH NASH Clinical Research network and an Advisory board member to Immuron.
https://www.bloomberg.com/research/stocks/people/person.asp?personId=60481092&privcapId=7687411

If Immuron has positive phase 2 NASH results expect a market cap of $1billion+. That is over 50x the current market cap.
Aside from this Immuron has ongoing sales from Travelan & Protectyn products, dual listed Nasdaq & Australian ASX. Cdiff looks like it works and phase 1/2 trial just commenced, results in 6-9months. This is worth hundreds of millions in market cap right now.
http://www.nextbiotech.com.au/imc-hits-key-milestones-ahead-imminent-nasdaq-listing/
http://www.immuron.com/assets/F105-Immuron-Bioshares-Presentation-July-21-2017.pdf
http://www.immuron.com/investor-centre/analyst-reports/

Stock tickers:
$IMRN on Nasdaq, warrants $IMRNW on Nasdaq
$IMC on ASX, $IMCOB options on the Australian exchange

As you can see from the lack of people on this board, Immuron is currently unheard of & underfollowed, hence massively undervalued.